Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: nivolumab
Drug: ipilimumab

First Posted Date: 2017-09-29

Last Posted Date: 2024-05-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 74

Registration Number: NCT03297593

Locations: 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Spital Thurgau, Frauenfeld, Switzerland
🇨🇭
Kantonsspital Baselland Bruderholz, Bruderholz, Switzerland

and more 11 locations

Adoptive Cell Therapy Across Cancer Diagnoses

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: Autologous tumor-infiltrating lymphocytes
Drug: Ipilimumab
Drug: Nivolumab
Drug: proleukin
Drug: Cyclophosphamide
Drug: Fludara

First Posted Date: 2017-09-28

Last Posted Date: 2024-10-26

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 25

Registration Number: NCT03296137

Locations: 🇩🇰
Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology, Copenhagen, Denmark

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1

Completed

Conditions: Metastatic Ovarian Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: TIL infusion
Drug: Interleukin-2
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2017-09-19

Last Posted Date: 2023-03-01

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 7

Registration Number: NCT03287674

Locations: 🇩🇰
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Denmark

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2017-09-18

Last Posted Date: 2024-02-16

Lead Sponsor: Greg Durm, MD

Target Recruit Count: 105

Registration Number: NCT03285321

Locations: 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive, Baltimore, Maryland, United States
🇺🇸
Michigan State University, Lansing, Michigan, United States

and more 9 locations

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Withdrawn

Conditions: Multiple Myeloma
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic

Interventions: Drug: Nivolumab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Ipilimumab

First Posted Date: 2017-09-14

Last Posted Date: 2017-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03283046

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Phase 2

Active, not recruiting

Conditions: Loss of INI 1 Protein Expression
Stage III Renal Cell Cancer AJCC v8
Kidney Medullary Carcinoma
Stage IV Renal Cell Cancer AJCC v8

Interventions: Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2017-09-06

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT03274258

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Phase 2

Completed

Conditions: MSS
RAS-mutant Colorectal Cancer

Interventions: Drug: binimetinib
Drug: nivolumab
Drug: ipilimumab

First Posted Date: 2017-09-01

Last Posted Date: 2022-01-04

Lead Sponsor: Pfizer

Target Recruit Count: 75

Registration Number: NCT03271047

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Siteman Cancer Center - South County, Saint Louis, Missouri, United States
🇪🇸
Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain

and more 46 locations

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Nivolumab
Drug: Carboplatin
Drug: Ipilimumab
Drug: pemetrexed

First Posted Date: 2017-08-21

Last Posted Date: 2020-11-04

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 9

Registration Number: NCT03256136

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States